Cartesian Therapeutics, Inc. (RNAC) just reported positive results from its phase 2 study using Descartes-08 for the treatment of patients with Myasthenia Gravis [MG]. These positive results translate ...

The last time I spoke about Cartesian Therapeutics (RNAC) it was in a Seeking Alpha article entitled "Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data." There, I wrote about ...

Track Cartesian Growth Corporation II Class A Ordinary Shares live price, charts, and news. Analyze Cartesian Growth Corporation II Class A Ordinary Shares forecasts, financials, technical indicators, ...

Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis (MG ...

A look at the shareholders of Cartesian Growth Corporation (NASDAQ:GLBL) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge companies ...